Patents Assigned to Prosidion Limited
  • Pyrrolopyridine-2-carboxylic acid amide derivative useful as inhibitor of glycogen phosphorylase
    Patent number: 8664397
    Abstract: The present invention is directed to a novel form of a pyrrolopyridine-2-carboxylic acid amide of formula (I), which is an inhibitor of glycogen phosphorylase, compositions containing it and their use in therapy. The invention is also directed to processes for production of the novel form, novel intermediates used in said processes and processes for the production of said intermediates.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: March 4, 2014
    Assignee: Prosidion Limited
    Inventors: Jozsef Repasi, Andras Szabo
  • Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders
    Patent number: 8278442
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful for the treatment of metabolic disorders including obesity.
    Type: Grant
    Filed: May 22, 2008
    Date of Patent: October 2, 2012
    Assignee: Prosidion Limited
    Inventors: Jason Bloxham, Stuart Edward Bradley, Tom Banksia Dupree, Peter Timothy Fry, Patrick Eric Hanrahan, Thomas Martin Krulle, Martin James Procter, Colin Peter Sambrook-Smith, Karen Lesley Schofield, Donald Smyth, Alan John Stewart
  • Aryl Urea Derivatives for Treating Obesity
    Publication number: 20120214808
    Abstract: A method of treating a condition associated with the CB-1 receptor, in particular obesity, by administering an effective amount of an aryl urea CB-1 receptor modulating compound to a subject in need of such treatment.
    Type: Application
    Filed: February 17, 2012
    Publication date: August 23, 2012
    Applicant: Prosidion Limited
    Inventors: Jason Bloxham, Matthew Colin Thor Fyfe, James Horswill, Revathy Perpetua Jeevaratnam, John Keily, Martin James Procter, Karen Lesley Schofield, Salam Shaaban, Simon Andrew Swain, Philippe Wong-Kai-In
  • GPCR Agonists
    Publication number: 20120172358
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.
    Type: Application
    Filed: February 14, 2012
    Publication date: July 5, 2012
    Applicant: Prosidion Limited
    Inventors: Stuart Edward Bradley, Matthew Colin Thor Fyfe, Lisa Sarah Bertram, William Gattrell, Revathy Perpetua Jeevaratnam, John Keily, Martin James Procter, Chrystelle Marie Rasamison, Philip John Rushworth, Colin Peter Sambrook-Smith, David French Stonehouse, Simon Andrew Swain, Geoffrey Martyn Williams
  • Heterocyclic derivatives as GPCR receptor agonists
    Patent number: 8207147
    Abstract: Compounds of Formula (I), R1-A-V—B—R2; or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful as regulators of satiety, e.g. for the treatment of obesity, and for the treatment of diabetes.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: June 26, 2012
    Assignee: Prosidion Limited
    Inventors: Matthew Colin Thor Fyfe, Lisa Sarah Gardner, John King-Underwood, Martin James Procter, Chrystelle Marie Rasamison, Karen Lesley Schofield, Gerard Hugh Thomas
  • G-protein coupled receptor agonists
    Patent number: 8193359
    Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.
    Type: Grant
    Filed: December 23, 2005
    Date of Patent: June 5, 2012
    Assignee: Prosidion Limited
    Inventors: Matthew Colin Thor Fyfe, Gerard Hugh Thomas, Lisa Sarah Bertram, Stuart Edward Bradley, William Gattrell, Chrystelle Marie Rasamison, Vilasben Kanji Shah
  • Pyridine, pyrimidine and pyrazine derivatives as GPCR agonists
    Patent number: 8173807
    Abstract: Compounds of formula (I): R1-A-V—B—R2, wherein V is phenyl or a 6-membered heteroaryl ring containing up to three N-atoms, or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.
    Type: Grant
    Filed: December 30, 2005
    Date of Patent: May 8, 2012
    Assignee: Prosidion Limited
    Inventors: Stuart Edward Bradley, Matthew Colin Thor Fyfe, Gerard Hugh Thomas
  • Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
    Patent number: 8158622
    Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: April 17, 2012
    Assignee: Prosidion Limited
    Inventors: Stuart Edward Bradley, Thomas Martin Krulle, Peter John Murray, Martin James Procter, Robert John Rowley, Colin Peter Sambrook Smith, Gerard Hugh Thomas, Karen Lesley Schofield
  • Compounds for the Treatment of Metabolic Disorders
    Publication number: 20120077793
    Abstract: The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.
    Type: Application
    Filed: March 12, 2010
    Publication date: March 29, 2012
    Applicant: PROSIDION LIMITED
    Inventors: Oscar Barba, Peter Timothy Fry, Matthew Colin Thor Fyfe, William Gattrell, Revathy Perpetua Jeevaratnam, Thomas Martin Krulle, Martin James Procter, Colin Peter Sambrook-Smith, Karen Lesley Schofield, Donald Smyth, Alan John William Stewart, David French Stonehouse, Simon Andrew Swain
  • Compounds for the Treatment of Metabolic Disorders
    Publication number: 20120059014
    Abstract: The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.
    Type: Application
    Filed: March 12, 2010
    Publication date: March 8, 2012
    Applicant: PROSIDION LIMITED
    Inventors: Oscar Barba, Tom Banksia Dupree, Peter Timothy Fry, Matthew Colin Thor Fyfe, Revathy Perpetua Jeevaratnam, Thomas Martin Krulle, Karen Lesley Schofield, Donald Smyth, Thomas Staroske, Alan John William Stewart, David French Stonehouse, Simon Andrew Swain, David Matthew Withall
  • Compounds for the Treatment of Metabolic Disorders
    Publication number: 20120040953
    Abstract: The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.
    Type: Application
    Filed: March 12, 2010
    Publication date: February 16, 2012
    Applicant: PROSIDION LIMITED
    Inventors: Oscar Barba, Susan Helen Davis, Matthew Colin Thor Fyfe, Revathy Perpetua Jeevaratnam, Karen Lesley Schofield, Thomas Staroske, Alan John William Stewart, Simon Andrew Swain, David Matthew Withall
  • Bicyclic aryl and heteroaryl receptor modulators
    Patent number: 8063247
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: November 22, 2011
    Assignee: Prosidion Limited
    Inventors: Jason Bloxham, Stuart Edward Bradley, Thomas Martin Krulle, Martin James Procter, Colin Peter Sambrook-Smith, Karen Lesley Schofield, Donald Smyth
  • PIPERIDINYL GPCR AGONISTS
    Publication number: 20110269734
    Abstract: Compounds of formula (I):or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of diabetes and obesity.
    Type: Application
    Filed: July 10, 2009
    Publication date: November 3, 2011
    Applicant: Prosidion Limited
    Inventors: Lisa Sarah Bertram, Matthew Colin Thor Fyfe, Revathy Perpetua Jeevaratnam, John Keily, Thomas Martin Krulle, Chrystelle Marie Rasamison, Colin Peter Sambrook-Smith, Simon Andrew Swain
  • Piperidine GPCR Agonists
    Publication number: 20110230507
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of diabetes and obesity.
    Type: Application
    Filed: July 10, 2009
    Publication date: September 22, 2011
    Applicant: Prosidion Limited
    Inventors: Lisa Sarah Bertram, Matthew Colin Thor Fyfe, Revathy Perpetua Jeevaratnam, John Keily
  • Heterocyclic GPCR Agonists
    Publication number: 20110212939
    Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.
    Type: Application
    Filed: July 10, 2009
    Publication date: September 1, 2011
    Applicant: Prosidion Limited
    Inventors: Lisa Sarah Bertram, Philip Graham Clarke, Graham John Dawson, Peter Timothy Fry, Matthew Colin Thor Fyfe, William Gattrell, Revathy Perpetua Jeevaratnam, John Keily, Thomas Martin Krulle, Martin James Procter, Chrystelle Marie Rasamison, Colin Peter Sambrook-Smith, Simon Andrew Swain
  • Piperidinyl GPCR Agonists
    Publication number: 20110195994
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of diabetes and obesity.
    Type: Application
    Filed: July 10, 2009
    Publication date: August 11, 2011
    Applicant: Prosidion Limited
    Inventors: Lisa Sarah Bertram, Matthew Colin Thor Fyfe
  • Heterocyclic GPCR Agonists
    Publication number: 20110178054
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR (GPR119) agonists and are useful as for the treatment of diabetes and obesity.
    Type: Application
    Filed: July 10, 2009
    Publication date: July 21, 2011
    Applicant: Prosidion Limited
    Inventors: Lisa Sarah Bertram, Matthew Colin Thor Fyfe, William Gattrell, Revathy P. Jeevaratnam, John Keily, Martin James Procter
  • Substituted phenylacetamides and their use as glucokinase activators
    Patent number: 7745491
    Abstract: Compounds of Formula (I) wherein R1 is a cycloalkylsulphonyl group, or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.
    Type: Grant
    Filed: August 9, 2005
    Date of Patent: June 29, 2010
    Assignee: Prosidion Limited
    Inventors: Matthew Colin Thor Fyfe, Vilasben Kanji Shah
  • AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES
    Publication number: 20100093733
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts and esters thereof, are useful for the treatment of obesity, type II diabetes and the metabolic syndrome.
    Type: Application
    Filed: February 15, 2008
    Publication date: April 15, 2010
    Applicant: PROSIDION LIMITED
    Inventors: Oscar Barba, Graham Dawson, William Gattrell, Martin James Procter, Chrystelle Marie Rasamison, Colin Peter Sambrook-Smith, Philippe Wong-Kai-In
  • HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS
    Publication number: 20090281060
    Abstract: Compounds of Formula (I), R1-A-V—B—R2; or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful as regulators of satiety, e.g. for the treatment of obesity, and for the treatment of diabetes.
    Type: Application
    Filed: December 23, 2004
    Publication date: November 12, 2009
    Applicant: PROSIDION LIMITED
    Inventors: Matthew Fyfe, John King-Underwood, Lisa Sarah Bertram (Gardner), Gerard Hugh Thomas, Martin Procter, Chrystelle Rasamison, Karen Schofield